Sino-Russian Comparison of Outcomes After Proximal Gastrectomy With Double-Tract Reconstruction

NCT07800819 · tracked via the Priya Life Science China tracker

Sponsor

The First Affiliated Hospital with Nanjing Medical University

Phase

Observational

Started

2026-08-15

Last updated

2026-09-02

Condition(s) studied

Gastric AdenocarcinomaAdenocarcinoma of the Esophagogastric Junction

Investigational drug(s) / intervention(s)

Proximal gastrectomy with double-tract reconstruction

Proximal gastrectomy with double-tract reconstruction: Curative proximal gastrectomy followed by double-tract reconstruction performed as part of routine clinical care. The study does not assign treatment and retrospectively analyzes existing clinical data.

Study summary

This two-center retrospective observational cohort study compares Chinese and Russian patients who underwent curative proximal gastrectomy with double-tract reconstruction for proximal gastric adenocarcinoma or Siewert type II/III adenocarcinoma of the esophagogastric junction. The study evaluates postoperative reflux, nutritional status, perioperative outcomes, complications, and long-term survival. Propensity score matching will be used to improve comparability between the two cohorts.

Eligibility

Sex

ALL

Min age

18 Years

Max age

75 Years

Healthy volunteers

Inclusion Criteria: 1. Age 18 to 75 years. 2. Histologically confirmed gastric adenocarcinoma or Siewert type II/III adenocarcinoma of the esophagogastric junction. 3. Underwent proximal gastrectomy with double-tract reconstruction. 4. Surgery performed with curative intent. 5. At least one valid postoperative follow-up record containing reflux, nutritional, or complication information. 6. Clinical, pathological, operative, and follow-up data sufficiently complete for analysis, with less than 20 percent missingness in key variables. Exclusion Criteria: 1. Previous gastric or esophageal surgery, except limited endoscopic treatment such as endoscopic mucosal resection. 2. Synchronous or metachronous malignancy, except cured non-melanoma skin cancer or cervical carcinoma in situ. 3. Complete absence of follow-up data. 4. Double-tract reconstruction not completed or changed to another reconstruction method. 5. Severe preoperative reflux disease, defined as GERD-Q score greater than 8 with a requirement for long-term medication.

Primary outcome measure(s)

Endoscopic reflux esophagitis — 1 year after surgery
Presence and severity of reflux esophagitis assessed by endoscopy using the Los Angeles classification (grades A-D).
Clinically significant reflux symptoms — 1 year after surgery
Reflux symptoms assessed using the GERD-Q questionnaire; a total score greater than 8 is considered clinically significant reflux.
Change in body mass index — From preoperative baseline to 1 year after surgery
Change in body mass index, measured in kilograms per square meter.
Change in serum albumin — From preoperative baseline to 1 year after surgery
Change in serum albumin concentration, measured in grams per liter.
Change in hemoglobin — From preoperative baseline to 1 year after surgery
Change in hemoglobin concentration, measured in grams per liter.

Trial sites (2)

Facility	City	Region	Status
First Affiliated Hospital of Nanjing Medical University	Nanjing	Jiangsu
Moscow Clinical Scientific Center named after A.S. Loginov	Moscow	Russia

More The First Affiliated Hospital with Nanjing Medical University trials in China

Efficacy and Safety of Intrathecal Administration of Thiotepa in Combination With Trastuzumab in Breast Cancer With Leptomeningeal Metastasis Recruiting

Clinical Study Protocol of IAV-induced Remission Followed by Consolidation Therapy With MDCyta+Ven in ND-AML Recruiting

Using ctDNA to Guide Treatment Decisions for Stage III Gastric Cancer Active, not recruiting

A Prospective, Single-arm, Phase II Clinical Study of Tislelizumab Combined With Anlotinib and Platinum-based Doublet Perioperative Therapy for Resectable Stage II-IIIB Driver Gene-negative NSCLC Starting soon

The Predictive Value of Molecular Diagnostic Techniques in the Antimicrobial- Resistance Phenotypes of Pathogens Enrolling by invitation

Other trials for the same condition

Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction Cancer Starting soon

Defining Benchmarks for Gastric Cancer Patients Underwent Minimal Invasive Gastrectomy Active, not recruiting

Iparomlimab and Tuvonralimab Injection (QL1706) Combined With DOS as Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Stomach and Gastroesophageal Junction Active, not recruiting

Fruquintinib Combined With Trastuzumab and XELOX as First-line Treatment in Patients With HER2-positive Advanced Gastric Cancer Recruiting

A Phase II, Multicenter, Randomized, Controlled Clinical Study Comparing the Efficacy and Safety of Sintilimab Plus SOX Versus SOX Alone as Adjuvant Therapy for PD-L1-Positive, Stage pN3 Gastric Cancer Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07800819 on ClinicalTrials.gov ↗ ← All trials in China